1
|
Flanagan DJ, Vincan E, Phesse TJ. Wnt Signaling in Cancer: Not a Binary ON:OFF Switch. Cancer Res 2019; 79:5901-5906. [PMID: 31431458 DOI: 10.1158/0008-5472.can-19-1362] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2019] [Revised: 07/16/2019] [Accepted: 08/07/2019] [Indexed: 11/16/2022]
Abstract
In the March 1 issue of Cancer Research, we identified the Wnt receptor Fzd7 as an attractive therapeutic target for the treatment of gastric cancer. In summary, we showed that pharmacological inhibition of Wnt receptors, or genetic deletion of Fzd7, blocks the initiation and growth of gastric tumors. Inhibiting Fzd receptors, specifically Fzd7, inhibits the growth of gastric cancer cells even in the presence of adenomatous polyposis coli (Apc) mutation. Apc is located in the cytoplasm downstream of Fzd7 in the Wnt signaling cascade and APC mutations activate Wnt/β-catenin signaling, therefore, this result seems counterintuitive. Here, we analyze this result in greater detail in the context of current knowledge of Wnt signaling and discuss the wider implications of this aspect of Wnt signaling in other cancers.
Collapse
Affiliation(s)
| | - Elizabeth Vincan
- University of Melbourne and Victorian Infectious Diseases Reference Laboratory, Doherty Institute of Infection and Immunity, Melbourne, Australia. .,School of Pharmacy and Biomedical Sciences, Curtin University, Perth, Australia
| | - Toby J Phesse
- European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, United Kingdom. .,Doherty Institute of Infection and Immunity, Melbourne, Australia
| |
Collapse
|
2
|
Kim S, Jeong S. Mutation Hotspots in the β-Catenin Gene: Lessons from the Human Cancer Genome Databases. Mol Cells 2019; 42:8-16. [PMID: 30699286 PMCID: PMC6354055 DOI: 10.14348/molcells.2018.0436] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Revised: 12/26/2018] [Accepted: 12/29/2018] [Indexed: 02/08/2023] Open
Abstract
Mutations in the β-catenin gene (CTNNB1) have been implicated in the pathogenesis of some cancers. The recent development of cancer genome databases has facilitated comprehensive and focused analyses on the mutation status of cancer-related genes. We have used these databases to analyze the CTNNB1 mutations assembled from different tumor types. High incidences of CTNNB1 mutations were detected in endometrial, liver, and colorectal cancers. This finding agrees with the oncogenic role of aberrantly activated β-catenin in epithelial cells. Elevated frequencies of missense mutations were found in the exon 3 of CTNNB1, which is responsible for encoding the regulatory amino acids at the N-terminal region of the protein. In the case of metastatic colorectal cancers, inframe deletions were revealed in the region spanning exon 3. Thus, exon 3 of CTNNB1 can be considered to be a mutation hotspot in these cancers. Since the N-terminal region of the β-catenin protein forms a flexible structure, many questions arise regarding the structural and functional impacts of hotspot mutations. Clinical identification of hotspot mutations could provide the mechanistic basis for an oncogenic role of mutant β-catenin proteins in cancer cells. Furthermore, a systematic understanding of tumor-driving hotspot mutations could open new avenues for precision oncology.
Collapse
Affiliation(s)
- Sewoon Kim
- Graduate Department of Bioconvergence Science and Technology, Dankook University, Jukjeon, Yongin, Gyeonggi 16890,
Korea
| | - Sunjoo Jeong
- Graduate Department of Bioconvergence Science and Technology, Dankook University, Jukjeon, Yongin, Gyeonggi 16890,
Korea
| |
Collapse
|
3
|
Zhang N, Wang LR, Li DD, Ma DN, Wang CH, He XG, Gao DM, Wang L, Tang ZY. Interferon-α Combined With Herbal Compound "Songyou Yin" Effectively Inhibits the Increased Invasiveness and Metastasis by Insufficient Radiofrequency Ablation of Hepatocellular Carcinoma in an Animal Model. Integr Cancer Ther 2018; 17:1260-1269. [PMID: 30234394 PMCID: PMC6247542 DOI: 10.1177/1534735418801525] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Objective: We had previously proved that insufficient radiofrequency
ablation (RFA) could enhance invasiveness and metastasis of hepatocellular
carcinoma (HCC) through epithelial-mesenchymal transition (EMT), which is
mediated by activating β-catenin signaling. Thus, the aim of the present study
was to demonstrate whether the combined treatment of interferon-α (IFN-α) and
“Songyou Yin” (SYY) minimizes the pro-metastatic effects of insufficient RFA, as
well as to explore its underlying mechanism. Methods: Insufficient
RFA was performed in an orthotopic nude mice model of HCCLM3 with high
metastatic potential. The effects of IFN-α, SYY, and combined IFN-α and SYY were
observed in the animal model. Tumor sizes, lung metastasis, and survival time
were assessed. Immunochemistry staining, real-time polymerase chain reaction,
and Western blot were used to examine gene expression related to metastasis and
angiogenesis in residual cancer after insufficient RFA. Results:
For up to 8 weeks of treatment, the combined therapy significantly decreased the
residual cancer sizes, minimized the lung metastasis rate, and prolonged the
survival time of nude mice, which might be due to suppression of the EMT via
β-catenin signal blockade, in addition to attenuating angiogenesis in residual
cancer after insufficient RFA. Conclusion: IFN-α combined with SYY
significantly weakened the enhanced metastatic potential of residual cancer
after insufficient RFA by attenuating EMT, which is mediated through inhibiting
activation of β-catenin. In addition, decreasing angiogenesis of residual cancer
might also play a certain role.
Collapse
Affiliation(s)
- Ning Zhang
- 1 Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.,2 Zhongshan Hospital, Liver Cancer Institute, Fudan University, Shanghai, People's Republic of China
| | - Long-Rong Wang
- 1 Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China
| | - Dou-Dou Li
- 1 Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China
| | - De-Ning Ma
- 3 Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China
| | - Cheng-Hao Wang
- 1 Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.,2 Zhongshan Hospital, Liver Cancer Institute, Fudan University, Shanghai, People's Republic of China
| | - Xi-Gan He
- 1 Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China
| | - Dong-Mei Gao
- 2 Zhongshan Hospital, Liver Cancer Institute, Fudan University, Shanghai, People's Republic of China
| | - Lu Wang
- 1 Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China
| | - Zhao-You Tang
- 2 Zhongshan Hospital, Liver Cancer Institute, Fudan University, Shanghai, People's Republic of China
| |
Collapse
|
4
|
Tan X, Liao Z, Liang H, Chen X, Zhang B, Chu L. Upregulation of liver kinase B1 predicts poor prognosis in hepatocellular carcinoma. Int J Oncol 2018; 53:1913-1926. [PMID: 30226588 PMCID: PMC6192789 DOI: 10.3892/ijo.2018.4556] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Accepted: 08/03/2018] [Indexed: 12/15/2022] Open
Abstract
The majority of studies report that liver kinase B1 (LKB1) acts as a tumor suppressor by inhibiting cell proliferation and metastasis. The present study investigated the expression pattern of LKB1 in 2 cohorts of paired hepatocellular carcinoma (HCC) and analogous non-cancerous tissues (ANT). The results indicated that LKB1 was upregulated in HCC vs. ANT tissues, and that high expression of LKB1 was associated with a higher number of tumor foci, larger tumor size, poorer tumor differentiation, Edmondson-Steiner grade, Barcelona Clinic Liver Cancer grade and tumor-node-metastasis stage. Furthermore, high LKB1 expression was associated with poor overall survival (OS), shorter disease-free survival and early recurrence. Univariate and multivariate analyses demonstrated that high LKB1 expression may serve as an independent prognostic marker for OS, but not for recurrence. In addition, knockdown of LKB1 expression in HCC cell lines inhibited cell proliferation and subcutaneous tumor growth by promoting cell apoptosis. Therefore, the findings of the present study suggest a protooncogenic role of LKB1 in HCC.
Collapse
Affiliation(s)
- Xiaolong Tan
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
| | - Zhibin Liao
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
| | - Huifang Liang
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
| | - Xiaoping Chen
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
| | - Bixiang Zhang
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
| | - Liang Chu
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
| |
Collapse
|
5
|
Tan SH, Barker N. Wnt Signaling in Adult Epithelial Stem Cells and Cancer. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2018; 153:21-79. [PMID: 29389518 DOI: 10.1016/bs.pmbts.2017.11.017] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Wnt/β-catenin signaling is integral to the homeostasis and regeneration of many epithelial tissues due to its critical role in adult stem cell regulation. It is also implicated in many epithelial cancers, with mutations in core pathway components frequently present in patient tumors. In this chapter, we discuss the roles of Wnt/β-catenin signaling and Wnt-regulated stem cells in homeostatic, regenerative and cancer contexts of the intestines, stomach, skin, and liver. We also examine the sources of Wnt ligands that form part of the stem cell niche. Despite the diversity in characteristics of various tissue stem cells, the role(s) of Wnt/β-catenin signaling is generally coherent in maintaining stem cell fate and/or promoting proliferation. It is also likely to play similar roles in cancer stem cells, making the pathway a salient therapeutic target for cancer. While promising progress is being made in the field, deeper understanding of the functions and signaling mechanisms of the pathway in individual epithelial tissues will expedite efforts to modulate Wnt/β-catenin signaling in cancer treatment and tissue regeneration.
Collapse
Affiliation(s)
- Si Hui Tan
- A*STAR Institute of Medical Biology, Singapore
| | - Nick Barker
- A*STAR Institute of Medical Biology, Singapore; Kanazawa University, Kanazawa, Japan; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
| |
Collapse
|
6
|
Teng YC, Shen ZQ, Kao CH, Tsai TF. Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol 2016; 22:300-325. [PMID: 26755878 PMCID: PMC4698494 DOI: 10.3748/wjg.v22.i1.300] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Revised: 10/14/2015] [Accepted: 11/24/2015] [Indexed: 02/06/2023] Open
Abstract
The multifactorial and multistage pathogenesis of hepatocellular carcinoma (HCC) has fascinated a wide spectrum of scientists for decades. While a number of major risk factors have been identified, their mechanistic roles in hepatocarcinogenesis still need to be elucidated. Many tumor suppressor genes (TSGs) have been identified as being involved in HCC. These TSGs can be classified into two groups depending on the situation with respect to allelic mutation/loss in the tumors: the recessive TSGs with two required mutated alleles and the haploinsufficient TSGs with one required mutated allele. Hepatitis B virus (HBV) is one of the most important risk factors associated with HCC. Although mice cannot be infected with HBV due to the narrow host range of HBV and the lack of a proper receptor, one advantage of mouse models for HBV/HCC research is the numerous and powerful genetic tools that help investigate the phenotypic effects of viral proteins and allow the dissection of the dose-dependent action of TSGs. Here, we mainly focus on the application of mouse models in relation to HBV-associated HCC and on TSGs that act either in a recessive or in a haploinsufficient manner. Discoveries obtained using mouse models will have a great impact on HCC translational medicine.
Collapse
|
7
|
Liu H, Wu L, Ji K, Wang W. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma. Tumour Biol 2015; 36:7375-84. [PMID: 26361957 DOI: 10.1007/s13277-015-4063-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Accepted: 09/04/2015] [Indexed: 01/02/2023] Open
Abstract
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor of the pleura closely related to asbestos exposure. Rare as it is, the incidence of MPM is predicted to increase mainly as a result of a lengthy latency period from the initial asbestos exposure, making it a public health concern for the next decades. Moreover, the patients with MPM have an extremely poor prognosis due to its high resistance to conventional oncologic treatments and delayed diagnosis. Although the result of current therapeutic modalities based on patient features and clinical stages is very frustrating, great advances have been shown in the knowledge of molecular biology of MPM in recent years. This is accompanied by dozens of putative prognostic biomarkers that are actively involved in tumor biological activities. These prognostic candidates can offer us a new insight into the biological characteristics of MPM, contributing to development of individualized therapeutic strategies directed against oncogenesis and tumor progression. Thus, personalized approaches based on the molecular biology of the patient's tissue or body fluid will potentially improve the present disappointing outcome, bringing new hope for patients with MPM. This article reviews the principal and several novel biomarkers that can have an influence on prognosis, in the hope that they can provide us with a more profound understanding of the biology of this lethal disease.
Collapse
Affiliation(s)
- Hui Liu
- Department of Respiratory Medicine, The Second Hospital of Shandong University, Jinan, 250033, People's Republic of China
| | - Licun Wu
- Latner Thoracic Surgery Research Laboratories and Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada
| | - Kai Ji
- Department of Endocrinology, Shengli Oilfield Central Hospital, Dongying, 257034, People's Republic of China
| | - Wei Wang
- Department of Respiratory Medicine, The Second Hospital of Shandong University, Jinan, 250033, People's Republic of China.
| |
Collapse
|
8
|
Monga SP. β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis. Gastroenterology 2015; 148:1294-310. [PMID: 25747274 PMCID: PMC4494085 DOI: 10.1053/j.gastro.2015.02.056] [Citation(s) in RCA: 498] [Impact Index Per Article: 55.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 02/21/2015] [Accepted: 02/23/2015] [Indexed: 12/11/2022]
Abstract
β-catenin (encoded by CTNNB1) is a subunit of the cell surface cadherin protein complex that acts as an intracellular signal transducer in the WNT signaling pathway; alterations in its activity have been associated with the development of hepatocellular carcinoma and other liver diseases. Other than WNT, additional signaling pathways also can converge at β-catenin. β-catenin also interacts with transcription factors such as T-cell factor, forkhead box protein O, and hypoxia inducible factor 1α to regulate the expression of target genes. We discuss the role of β-catenin in metabolic zonation of the adult liver. β-catenin also regulates the expression of genes that control metabolism of glucose, nutrients, and xenobiotics; alterations in its activity may contribute to the pathogenesis of nonalcoholic steatohepatitis. Alterations in β-catenin signaling may lead to activation of hepatic stellate cells, which is required for fibrosis. Many hepatic tumors such as hepatocellular adenomas, hepatocellular cancers, and hepatoblastomas have mutations in CTNNB1 that result in constitutive activation of β-catenin, so this molecule could be a therapeutic target. We discuss how alterations in β-catenin activity contribute to liver disease and how these might be used in diagnosis and prognosis, as well as in the development of therapeutics.
Collapse
Affiliation(s)
- Satdarshan Pal Monga
- Department of Pathology and Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
| |
Collapse
|
9
|
Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis. Nat Commun 2015; 6:5944. [PMID: 25661872 PMCID: PMC4324535 DOI: 10.1038/ncomms6944] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2014] [Accepted: 11/24/2014] [Indexed: 02/07/2023] Open
Abstract
Aberrant β-catenin activation contributes to a third or more of human hepatocellular carcinoma (HCC), but β-catenin activation alone is not sufficient to induce liver cancer in mice. Differentiated hepatocytes proliferate upon acute activation of either β-catenin or the nuclear xenobiotic receptor CAR. These responses are strictly limited and are tightly linked, since β-catenin is activated in nearly all of the CAR-dependent tumors generated by the tumor promoter phenobarbital. Here we show that full activation of β-catenin in the liver induces senescence and growth arrest, which is overcome by combined CAR activation, resulting in uncontrolled hepatocyte proliferation, hepatomegaly, and rapid lethality despite maintenance of normal liver function. Combining CAR activation with limited β-catenin activation induces tumorigenesis, and the tumors share a conserved gene expression signature with β-catenin positive human HCC. These results reveal an unexpected route for hepatocyte proliferation and define a murine model of hepatocarcinogenesis with direct relevance to human HCC.
Collapse
|
10
|
Chan KT, Asokan SB, King SJ, Bo T, Dubose ES, Liu W, Berginski ME, Simon JM, Davis IJ, Gomez SM, Sharpless NE, Bear JE. LKB1 loss in melanoma disrupts directional migration toward extracellular matrix cues. ACTA ACUST UNITED AC 2015; 207:299-315. [PMID: 25349262 PMCID: PMC4210439 DOI: 10.1083/jcb.201404067] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The LKB1 kinase regulates directional migration in response to extracellular matrix gradients and may inhibit invasive motility by sensing inhibitory matrix cues. Somatic inactivation of the serine/threonine kinase gene STK11/LKB1/PAR-4 occurs in a variety of cancers, including ∼10% of melanoma. However, how the loss of LKB1 activity facilitates melanoma invasion and metastasis remains poorly understood. In LKB1-null cells derived from an autochthonous murine model of melanoma with activated Kras and Lkb1 loss and matched reconstituted controls, we have investigated the mechanism by which LKB1 loss increases melanoma invasive motility. Using a microfluidic gradient chamber system and time-lapse microscopy, in this paper, we uncover a new function for LKB1 as a directional migration sensor of gradients of extracellular matrix (haptotaxis) but not soluble growth factor cues (chemotaxis). Systematic perturbation of known LKB1 effectors demonstrated that this response does not require canonical adenosine monophosphate–activated protein kinase (AMPK) activity but instead requires the activity of the AMPK-related microtubule affinity-regulating kinase (MARK)/PAR-1 family kinases. Inhibition of the LKB1–MARK pathway facilitated invasive motility, suggesting that loss of the ability to sense inhibitory matrix cues may promote melanoma invasion.
Collapse
Affiliation(s)
- Keefe T Chan
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Sreeja B Asokan
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Samantha J King
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Tao Bo
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Evan S Dubose
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Wenjin Liu
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Matthew E Berginski
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Jeremy M Simon
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Ian J Davis
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Shawn M Gomez
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Norman E Sharpless
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - James E Bear
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| |
Collapse
|
11
|
Zhang N, Wang L, Chai ZT, Zhu ZM, Zhu XD, Ma DN, Zhang QB, Zhao YM, Wang M, Ao JY, Ren ZG, Gao DM, Sun HC, Tang ZY. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling. PLoS One 2014; 9:e115949. [PMID: 25542041 PMCID: PMC4277411 DOI: 10.1371/journal.pone.0115949] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2014] [Accepted: 11/27/2014] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND Radiofrequency ablation (RFA) is one of the curative therapies for hepatocellular carcinoma (HCC), however, accelerated progression of residual HCC after incomplete RFA has been reported more frequently. The underlying molecular mechanism of this phenomenon remains to be elucidated. In this study, we used an incomplete RFA orthotopic HCC nude mouse model to study the invasive and metastatic potential of residual cancer as well as the correlated mechanism. METHODS The incomplete RFA orthotopic nude mouse models were established using high metastatic potential HCC cell line HCCLM3 and low metastatic potential HCC cell line HepG2, respectively. The changes in cellular morphology, motility, metastasis and epithelial-mesenchymal transition (EMT), and HCC cell molecular markers after in vitro and in vivo incomplete RFA intervention were observed. RESULTS Pulmonary and intraperitoneal metastasis were observed in an in vivo study. The underlying pro-invasive mechanism of incomplete RFA appeared to be associated with promoting EMT, including down-regulation of E-cadherin and up-regulation of N-cadherin and vimentin. These results were in accordance with the in vitro response of HCC cells to heat intervention. Further studies demonstrated that β-catenin was a pivotal factor during this course and blocking β-catenin reduced metastasis and EMT phenotype changes in heat-treated HCCLM3 cells in vitro. CONCLUSION Incomplete RFA enhanced the invasive and metastatic potential of residual cancer, accompanying with EMT-like phenotype changes by activating β-catenin signaling in HCCLM3 cells.
Collapse
Affiliation(s)
- Ning Zhang
- Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, P. R. China
| | - Lu Wang
- Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, P. R. China
| | - Zong-Tao Chai
- Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, P. R. China
| | - Zi-Man Zhu
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing, P. R. China
| | - Xiao-Dong Zhu
- Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, P. R. China
| | - De-Ning Ma
- Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, P. R. China
| | - Qiang-Bo Zhang
- Department of General Surgery, Qilu Hospital, Shandong University, Jinan, P. R. China
| | - Yi-Ming Zhao
- Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, P. R. China
| | - Miao Wang
- Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, P. R. China
| | - Jian-Yang Ao
- Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, P. R. China
| | - Zheng-Gang Ren
- Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, P. R. China
| | - Dong-Mei Gao
- Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, P. R. China
| | - Hui-Chuan Sun
- Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, P. R. China
| | - Zhao-You Tang
- Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, P. R. China
| |
Collapse
|
12
|
Shi QQ, Zuo GW, Feng ZQ, Zhao LC, Luo L, You ZM, Li DY, Xia J, Li J, Chen DL. Effect of Trichostatin A on Anti HepG2 Liver Carcinoma Cells: Inhibition of HDAC Activity and Activation of Wnt/β-Catenin Signaling. Asian Pac J Cancer Prev 2014; 15:7849-55. [DOI: 10.7314/apjcp.2014.15.18.7849] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
13
|
Otterstrom C, Soltermann A, Opitz I, Felley-Bosco E, Weder W, Stahel RA, Triponez F, Robert JH, Serre-Beinier V. CD74: a new prognostic factor for patients with malignant pleural mesothelioma. Br J Cancer 2014; 110:2040-6. [PMID: 24594996 PMCID: PMC3992494 DOI: 10.1038/bjc.2014.117] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2013] [Revised: 11/28/2013] [Accepted: 02/10/2014] [Indexed: 12/29/2022] Open
Abstract
Background: The pro-inflammatory cytokine migration inhibitory factor (MIF) and its receptor CD74 have been proposed as possible therapeutic targets in several cancers. We studied the expression of MIF and CD74 together with calretinin in specimens of malignant pleural mesothelioma (MPM), correlating their expression levels with clinico-pathologic parameters, in particular overall survival (OS). Methods: Migration inhibitory factor, CD74, and calretinin immunoreactivity were investigated in a tissue microarray of 352 patients diagnosed with MPM. Protein expression intensities were semiquantitatively scored in the tumour cells and in the peritumoral stroma. Markers were matched with OS, age, gender, and histological subtype. Results: Clinical data from 135 patients were available. Tumour cell expressions of MIF and CD74 were observed in 95% and 98% of MPM specimens, respectively, with a homogenous distribution between the different histotypes. CD74 (P<0.001) but not MIF overexpression (P=0.231) emerged as an independent prognostic factor for prolonged OS. High expression of tumour cell calretinin correlated with the epithelioid histotype and was also predictive of longer OS (P<0.001). When compared with previously characterised putative epithelial-to-mesenchymal transition markers, CD74 correlated positively with tumoral PTEN and podoplanin expressions, but was inversely related with periostin expression. Conclusions: High expression of CD74 is an independent prognostic factor for prolonged OS in mesothelioma patients.
Collapse
Affiliation(s)
- C Otterstrom
- Division of Thoracic Surgery, University Hospitals of Geneva, Geneva, Switzerland
| | - A Soltermann
- Institute of Surgical Pathology, University Hospital Zürich, Zürich, Switzerland
| | - I Opitz
- Division of Thoracic Surgery, University Hospital Zürich, Zürich, Switzerland
| | - E Felley-Bosco
- Laboratory of Molecular Oncology, Clinic for Oncology, University Hospital Zürich, Zürich, Switzerland
| | - W Weder
- Division of Thoracic Surgery, University Hospital Zürich, Zürich, Switzerland
| | - R A Stahel
- Laboratory of Molecular Oncology, Clinic for Oncology, University Hospital Zürich, Zürich, Switzerland
| | - F Triponez
- Division of Thoracic Surgery, University Hospitals of Geneva, Geneva, Switzerland
| | - J H Robert
- Division of Thoracic Surgery, University Hospitals of Geneva, Geneva, Switzerland
| | - V Serre-Beinier
- Division of Thoracic Surgery, University Hospitals of Geneva, Geneva, Switzerland
| |
Collapse
|
14
|
Huang YH, Chen ZK, Huang KT, Li P, He B, Guo X, Zhong JQ, Zhang QY, Shi HQ, Song QT, Yu ZP, Shan YF. Decreased expression of LKB1 correlates with poor prognosis in hepatocellular carcinoma patients undergoing hepatectomy. Asian Pac J Cancer Prev 2014; 14:1985-8. [PMID: 23679304 DOI: 10.7314/apjcp.2013.14.3.1985] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
AIM To study any correlation of LKB1 expression with prognosis in hepatocellular carcinoma (HCC) cases. METHODS A total of 70 HCC patients and 20 primary intrahepatic stone patients in the first affiliated hospital of Wenzhou Medical College were enrolled in this study. LKB1 expression was detected by immunohistochemistry. Patients were followed-up and prognostic factors were evaluated. RESULT LKB1 expression was decreased in the HCC samples. Loss of LKB1 expression in HCC was significantly related to histologic grade (P=0.010), vascular invasion (P=0.025) and TMN stage (P=0.011). Patients showing negative LKB1 expression had a significantly shorter disease-free and overall survival than those with positive expression (P = 0.001, P=0.000, respectively). Multivariate Cox regression analysis indicated that LKB1 expression level was an independent factor of survival (P = 0.033). CONCLUSION HCC patients with decreased expression LKB1 have a poor prognosis. The loss of LKB1 expression is correlated with a lower survival rate.
Collapse
Affiliation(s)
- Yue-Han Huang
- Department of Hepatobiliary, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol 2013; 59:1107-17. [PMID: 23835194 DOI: 10.1016/j.jhep.2013.07.001] [Citation(s) in RCA: 204] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/25/2013] [Revised: 06/26/2013] [Accepted: 07/02/2013] [Indexed: 12/25/2022]
Abstract
Hepatocellular carcinoma (HCC) is one of the most common causes of cancer death worldwide. HCC can be cured by radical therapies if early diagnosis is done while the tumor has remained of small size. Unfortunately, diagnosis is commonly late when the tumor has grown and spread. Thus, palliative approaches are usually applied such as transarterial intrahepatic chemoembolization and sorafenib, an anti-angiogenic agent and MAP kinase inhibitor. This latter is the only targeted therapy that has shown significant, although moderate, efficiency in some individuals with advanced HCC. This highlights the need to develop other targeted therapies, and to this goal, to identify more and more pathways as potential targets. The Wnt pathway is a key component of a physiological process involved in embryonic development and tissue homeostasis. Activation of this pathway occurs when a Wnt ligand binds to a Frizzled (FZD) receptor at the cell membrane. Two different Wnt signaling cascades have been identified, called non-canonical and canonical pathways, the latter involving the β-catenin protein. Deregulation of the Wnt pathway is an early event in hepatocarcinogenesis and has been associated with an aggressive HCC phenotype, since it is implicated both in cell survival, proliferation, migration and invasion. Thus, component proteins identified in this pathway are potential candidates of pharmacological intervention. This review focuses on the characteristics and functions of the molecular targets of the Wnt signaling cascade and how they may be manipulated to achieve anti-tumor effects.
Collapse
Affiliation(s)
- Floriane Pez
- INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, F-69008 Lyon, France; Université Lyon-1, F-69622 Villeurbanne, France; Centre Léon Bérard, F-69008 Lyon, France
| | | | | | | | | | | |
Collapse
|
16
|
Hussain I, Eloy JA, Carmel PW, Liu JK. Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies. J Neurosurg 2013; 119:106-12. [PMID: 23560577 DOI: 10.3171/2013.3.jns122214] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Craniopharyngiomas are benign intracranial tumors that arise in the suprasellar and intrasellar region in children and adults. They are associated with calcification on neuroimaging, endocrinopathies, vision problems, and recurrence following subtotal resection. Molecular studies into their genetic basis have been limited, and therefore targeted medical therapies for this tumor have eluded physicians. With the discovery of aberrant Wnt/β-catenin pathway signaling in the pathogenesis of the most common subtype of craniopharyngioma (adamantinomatous), the identification of candidate genes and proteins implicated in this cascade provide attractive targets for future therapies. The recent development of a genetically engineered animal model of this tumor may also serve as a platform for evaluating potential therapies prior to clinical trials in humans. Advances in understanding the molecular pathogenesis of tumor recurrence have also been made, providing clues to develop adjuvant and neoadjuvant therapies to couple with tumor resection for optimal response rates. Finally, advances in genomic technologies and next-generation sequencing will underlie the translation of these genetic and molecular studies from the bench to clinical practice. In this review, the authors present an analysis of the molecular oncogenesis of craniopharyngioma and current directions in the development of novel therapies for these morbid, yet poorly understood brain tumors.
Collapse
Affiliation(s)
- Ibrahim Hussain
- Department of Neurological Surgery, Neurological Institute of New Jersey, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ 07103, USA
| | | | | | | |
Collapse
|
17
|
Chang HW, Lee YS, Nam HY, Han MW, Kim HJ, Moon SY, Jeon H, Park JJ, Carey TE, Chang SE, Kim SW, Kim SY. Knockdown of β-catenin controls both apoptotic and autophagic cell death through LKB1/AMPK signaling in head and neck squamous cell carcinoma cell lines. Cell Signal 2012; 25:839-47. [PMID: 23280187 DOI: 10.1016/j.cellsig.2012.12.020] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2012] [Revised: 12/06/2012] [Accepted: 12/24/2012] [Indexed: 11/24/2022]
Abstract
The Wnt/β-catenin pathway regulates the viability and radiosensitivity of head and neck squamous cancer cells (HNSCC). Increased β-catenin predisposes HNSCC patients to poor prognosis and survival. This study was conducted to determine the mechanism by which β-catenin regulates the viability of HNSCC. AMC-HN-3, -HN-8, UM-SCC-38, and -SCC-47 cells, which were established from human head and neck cancer specimens, and underwent cell death following β-catenin silencing. β-Catenin silencing significantly induced G1 arrest and increased the expression of Bax and active caspase-3, which demonstrates the sequential activation of apoptotic cascades following treatment of HNSCC with targeted siRNA. Intriguingly, β-catenin silencing also induced autophagy. Here, we confirm that the number of autophagic vacuoles and the expression of type II light chain 3 were increased in cells that were treated with β-catenin siRNA. These cell death modes are most likely due to the activation of LKB1-dependent AMPK following β-catenin silencing. The activated LKB1/AMPK pathway in AMC-HN-3 cells caused G1 arrest by phosphorylating p53 and suppressing mTOR signaling. In addition, treating AMC-HN-3 cells with LKB1 siRNA preserved cell viability against β-catenin silencing-induced cytotoxicity. Taken together, these results imply that following β-catenin silencing, HNSCC undergo both apoptotic and autophagic cell death that are under the control of LKB1/AMPK. To the best of our knowledge, these results suggest for the first time that novel crosstalk between β-catenin and the LKB1/AMPK pathway regulates the viability of HNSCC. This study thus presents new insights into our understanding of the cellular and molecular mechanisms involved in β-catenin silencing-induced cell death.
Collapse
Affiliation(s)
- Hyo Won Chang
- Department of Otolaryngology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
BIOLOGICAL TARGETS OF OXIDATIVE STRESS Oxidative Post-translational Protein Modifi cations (OPMs). Cancer Biomark 2012. [DOI: 10.1201/b14318-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
19
|
Awuah PK, Rhieu BH, Singh S, Misse A, Monga SPS. β-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice. PLoS One 2012; 7:e39771. [PMID: 22761897 PMCID: PMC3382575 DOI: 10.1371/journal.pone.0039771] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2012] [Accepted: 05/30/2012] [Indexed: 02/06/2023] Open
Abstract
Hepatocellular Carcinoma (HCC) is the fifth most common cancer worldwide. β-Catenin, the central orchestrator of the canonical Wnt pathway and a known oncogene is paramount in HCC pathogenesis. Administration of phenobarbital (PB) containing water (0.05% w/v) as tumor promoter following initial injected intraperitoneal (IP) diethylnitrosamine (DEN) injection (5 µg/gm body weight) as a tumor inducer is commonly used model to study HCC in mice. Herein, nine fifteen-day male β-catenin knockout mice (KO) and fifteen wild-type littermate controls (WT) underwent DEN/PB treatment and were examined for hepatic tumorigenesis at eight months. Paradoxically, a significantly higher tumor burden was observed in KO (p<0.05). Tumors in KO were β-catenin and glutamine synthetase negative and HGF/Met, EGFR & IGFR signaling was unremarkable. A significant increase in PDGFRα and its ligand PDGF-CC leading to increased phosphotyrosine-720-PDGFRα was observed in tumor-bearing KO mice (p<0.05). Simultaneously, these livers displayed increased cell death, stellate cell activation, hepatic fibrosis and cell proliferation. Further, PDGF-CC significantly induced hepatoma cell proliferation especially following β-catenin suppression. Our studies also demonstrate that the utilized DEN/PB protocol in the WT C57BL/6 mice did not select for β-catenin gene mutations during hepatocarcinogenesis. Thus, DEN/PB enhanced HCC in mice lacking β-catenin in the liver may be due to their ineptness at regulating cell survival, leading to enhanced fibrosis and regeneration through PDGFRα activation. β-Catenin downregulation also made hepatoma cells more sensitive to receptor tyrosine kinases and thus may be exploited for therapeutics.
Collapse
Affiliation(s)
- Prince Kwaku Awuah
- Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
| | - Byung Han Rhieu
- Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
| | - Sucha Singh
- Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
| | - Amalea Misse
- Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
| | - Satdarshan P. S. Monga
- Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
- * E-mail:
| |
Collapse
|
20
|
White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology 2012; 142:219-32. [PMID: 22155636 PMCID: PMC3285553 DOI: 10.1053/j.gastro.2011.12.001] [Citation(s) in RCA: 370] [Impact Index Per Article: 30.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2011] [Revised: 11/28/2011] [Accepted: 12/05/2011] [Indexed: 12/20/2022]
Abstract
Aberrant Wnt/β-catenin signaling is widely implicated in numerous malignancies, including cancers of the gastrointestinal tract. Dysregulation of signaling is traditionally attributed to mutations in Axin, adenomatous polyposis coli, and β-catenin that lead to constitutive hyperactivation of the pathway. However, Wnt/β-catenin signaling is also modulated through various other mechanisms in cancer, including cross talk with other altered signaling pathways. A more complex view of Wnt/β-catenin signaling and its role in gastrointestinal cancers is now emerging as divergent phenotypic outcomes are found to be dictated by temporospatial context and relative levels of pathway activation. This review summarizes the dysregulation of Wnt/β-catenin signaling in colorectal carcinoma, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, with particular emphasis on the latter two. We conclude by addressing some of the major challenges faced in attempting to target the pathway in the clinic.
Collapse
Affiliation(s)
- Bryan D. White
- Science and Technology Program University of Washington Bothell Bothell, WA, USA
| | - Andy J. Chien
- Department of Medicine, Division of Dermatology Institute for Stem Cell and Regenerative Medicine University of Washington School of Medicine Seattle, WA, USA
| | - David W. Dawson
- Department of Pathology and Laboratory Medicine Jonsson Comprehensive Cancer Center The David Geffen School of Medicine at UCLA Los Angeles, CA, USA
| |
Collapse
|
21
|
Ollila S, Mäkelä TP. The tumor suppressor kinase LKB1: lessons from mouse models. J Mol Cell Biol 2011; 3:330-40. [PMID: 21926085 DOI: 10.1093/jmcb/mjr016] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Mutations in the tumor suppressor gene LKB1 are important in hereditary Peutz-Jeghers syndrome, as well as in sporadic cancers including lung and cervical cancer. LKB1 is a kinase-activating kinase, and a number of LKB1-dependent phosphorylation cascades regulate fundamental cellular and organismal processes in at least metabolism, polarity, cytoskeleton organization, and proliferation. Conditional targeting approaches are beginning to demonstrate the relevance and specificity of these signaling pathways in development and homeostasis of multiple organs. More than one of the pathways also appear to contribute to tumor growth following Lkb1 deficiencies based on a number of mouse tumor models. Lkb1-dependent activation of AMPK and subsequent inactivation of mammalian target of rapamycin signaling are implicated in several of the models, and other less well characterized pathways are also involved. Conditional targeting studies of Lkb1 also point an important role of LKB1 in epithelial-mesenchymal interactions, significantly expanding knowledge on the relevance of LKB1 in human disease.
Collapse
Affiliation(s)
- Saara Ollila
- Institute of Biotechnology, University of Helsinki, Viikki Biocenter, Viikinkaari 9B, FIN-00014, Helsinki, Finland
| | | |
Collapse
|
22
|
Filipovich A, Gehrke I, Poll-Wolbeck SJ, Kreuzer KA. Physiological inhibitors of Wnt signaling. Eur J Haematol 2011; 86:453-65. [PMID: 21342268 DOI: 10.1111/j.1600-0609.2011.01592.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Wnt signaling is crucial for cell proliferation and differentiation. It represents a complex network with mechanisms of self-regulation through positive and negative feedback. Recent increasing interest in this signaling pathway has led to the discovery of many new proteins that down-regulate Wnt activity. Here, we provide a short description of the most important and best-studied inhibitors, group them according to the target molecule within the Wnt cascade, and discuss their clinical potential. Although most of the inhibitors discussed here may also interact with proteins from other signaling pathways, we focus only on their ability to modulate Wnt signaling.
Collapse
|
23
|
Herrmann JL, Byekova Y, Elmets CA, Athar M. Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers. Cancer Lett 2011; 306:1-9. [PMID: 21450399 DOI: 10.1016/j.canlet.2011.01.014] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2010] [Revised: 01/16/2011] [Accepted: 01/19/2011] [Indexed: 12/26/2022]
Abstract
LKB1 acts as a master kinase, with its major protein targets being the family of AMPKs. Through activation of multiple signaling pathways, LKB1's main physiologic functions involve regulating cellular growth, metabolism, and polarity. Germline mutations in LKB1 result in Peutz-Jeghers Syndrome, a rare cancer susceptibility syndrome. In addition, multiple LKB1 mutations have been identified in sporadic cancers, especially those of the lung. Recent studies from a variety of murine models have helped characterize LKB1's role in the pathogenesis of epithelial cancers. In some tumor types, LKB1 might function chiefly to suppress cell growth or invasion, while in other cases, it may serve to prevent metastasis. Moreover, molecular signatures of individual tumors likely influence LKB1's operational role, as multiple studies have shown that LKB1 can synergize with other tumor suppressors and/or oncogenes to accelerate tumorigenesis. To date, LKB1 has been considered mainly a tumor suppressor; however, some studies have suggested its potential oncogenic role, mainly through the suppression of apoptosis. In short, LKB1 is a tissue and context-specific kinase. This review aims to summarize our current understanding of its role in the pathogenesis of epithelial cancers.
Collapse
|
24
|
Stein TJ, Jochem A, Holmes KE, Sandgren EP. Effect of mutant β-catenin on liver growth homeostasis and hepatocarcinogenesis in transgenic mice. Liver Int 2011; 31:303-12. [PMID: 21281430 PMCID: PMC3093768 DOI: 10.1111/j.1478-3231.2010.02430.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
BACKGROUND Mutations in the Wnt signalling pathway molecule β-catenin are associated with liver cancer. AIMS Our aim was to confirm the effects of stabilized β-catenin on liver growth, identify whether those effects were reversible and cell autonomous or non-cell autonomous and to model β-catenin-induced liver cancer in mice. METHODS Using a liver-specific inducible promoter, we generated transgenic mice in which the expression of mutant β-catenin can be induced or repressed within hepatocytes in mice of different ages. RESULTS Similar to other models, the hepatic expression of mutant β-catenin in our model beginning in utero or induced in quiescent adult liver resulted in a two-fold liver enlargement and development of disease with a latency of 1-5 months, and mice displayed elevated blood ammonia and altered hepatic gene expression. Our model additionally allowed us to discover that molecular and phenotypic abnormalities were reversible following the inhibition of transgene expression. Hepatocyte transplant studies indicated that mutant β-catenin could not increase the growth of transgene-expressing foci in either growth-permissive or -restrictive hepatic environments, but still directly altered hepatocyte gene expression. Mice with continuous but focal transgene expression developed hepatic neoplasms after the age of 1 year. CONCLUSIONS Our findings indicate that hepatocyte gene expression is directly affected by mutant β-catenin in a cell autonomous manner. However, hepatomegaly associated with diffuse hepatocyte-specific expression of mutant β-catenin is secondary to liver functional alteration or non-cell autonomous. Both phenotypes are reversible. Nevertheless, some foci of transgene-expressing cells progressed to carcinoma, confirming the association of mutant β-catenin with liver cancer.
Collapse
Affiliation(s)
- Timothy J. Stein
- Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA
| | - Adam Jochem
- Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA
| | - Katie E. Holmes
- Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA
| | - Eric P. Sandgren
- Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA
| |
Collapse
|
25
|
Nejak-Bowen KN, Monga SPS. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 2010; 21:44-58. [PMID: 21182948 DOI: 10.1016/j.semcancer.2010.12.010] [Citation(s) in RCA: 194] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2010] [Revised: 12/09/2010] [Accepted: 12/14/2010] [Indexed: 12/19/2022]
Abstract
Among the adult organs, liver is unique for its ability to regenerate. A concerted signaling cascade enables optimum initiation of the regeneration process following insults brought about by surgery or a toxicant. Additionally, there exists a cellular redundancy, whereby a transiently amplifying progenitor population appears and expands to ensure regeneration, when differentiated cells of the liver are unable to proliferate in both experimental and clinical scenarios. One such pathway of relevance in these phenomena is Wnt/β-catenin signaling, which is activated relatively early during regeneration mostly through post-translational modifications. Once activated, β-catenin signaling drives the expression of target genes that are critical for cell cycle progression and contribute to initiation of the regeneration process. The role and regulation of Wnt/β-catenin signaling is now documented in rats, mice, zebrafish and patients. More recently, a regenerative advantage of the livers in β-catenin overexpressing mice was reported, as was also the case after exogenous Wnt-1 delivery to the liver paving the way for assessing means to stimulate the pathway for therapeutics in liver failure. β-Catenin is also pertinent in hepatic oval cell activation and differentiation. However, aberrant activation of the Wnt/β-catenin signaling is reported in a significant subset of hepatocellular cancers (HCC). While many mechanisms of such activation have been reported, the most functional means of aberrant and sustained activation is through mutations in the β-catenin gene or in AXIN1/2, which encodes for a scaffolding protein critical for β-catenin degradation. Intriguingly, in experimental models hepatic overexpression of normal or mutant β-catenin is insufficient for tumorigenesis. In fact β-catenin loss promoted chemical carcinogenesis in the liver due to alternate mechanisms. Since most HCC occur in the backdrop of chronic hepatic injury, where hepatic regeneration is necessary for maintenance of liver function, but at the same time serves as the basis of dysplastic changes, this Promethean attribute exhibits a Jekyll and Hyde behavior that makes distinguishing good regeneration from bad regeneration essential for targeting selective molecular pathways as personalized medicine becomes a norm in clinical practice. Could β-catenin signaling be one such pathway that may be redundant in regeneration and indispensible in HCC in a subset of cases?
Collapse
|
26
|
Nejak-Bowen KN, Thompson MD, Singh S, Bowen WC, Dar MJ, Khillan J, Dai C, Monga SPS. Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. Hepatology 2010; 51:1603-13. [PMID: 20432254 PMCID: PMC2908905 DOI: 10.1002/hep.23538] [Citation(s) in RCA: 128] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
UNLABELLED The Wnt/beta-catenin pathway is implicated in the pathogenesis of hepatocellular cancer (HCC). We developed a transgenic mouse (TG) in the FVB strain that overexpresses Ser45-mutated-beta-catenin in hepatocytes to study the effects on liver regeneration and cancer. In the two independent TG lines adult mice show elevated beta-catenin at hepatocyte membrane with no increase in the Wnt pathway targets cyclin-D1 or glutamine synthetase. However, TG hepatocytes upon culture exhibit a 2-fold increase in thymidine incorporation at day 5 (D5) when compared to hepatocytes from wildtype FVB mice (WT). When subjected to partial hepatectomy (PH), dramatic increases in the number of hepatocytes in S-phase are evident in TG at 40 and WT at 72 hours. Coincident with the earlier onset of proliferation, we observed nuclear translocation of beta-catenin along with an increase in total and nuclear cyclin-D1 protein at 40 hours in TG livers. To test if stimulation of beta-catenin induces regeneration, we used hydrodynamic delivery of Wnt-1 naked DNA to control mice, which prompted an increase in Wnt-1, beta-catenin, and known targets, glutamine synthetase (GS) and cyclin-D1, along with a concomitant increase in cell proliferation. beta-Catenin-overexpressing TG mice, when followed up to 12 months, showed no signs of spontaneous tumorigenesis. However, intraperitoneal delivery of diethylnitrosamine (DEN), a known carcinogen, induced HCC at 6 months in TG mice only. Tumors in TG livers showed up-regulation of beta-catenin, cyclin-D1, and unique genetic aberrations, whereas other canonical targets were unremarkable. CONCLUSION beta-Catenin overexpression offers growth advantage during liver regeneration. Also, whereas no spontaneous HCC is evident, beta-catenin overexpression makes TG mice susceptible to DEN-induced HCC.
Collapse
Affiliation(s)
- Kari N Nejak-Bowen
- Department of Pathology University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania
| | - Michael D. Thompson
- Department of Pathology University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania
| | - Sucha Singh
- Department of Pathology University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania
| | - William C. Bowen
- Department of Pathology University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania
| | - Mohd Jamal Dar
- Department of Pathology University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania
| | - Jaspal Khillan
- Molecular Genetics and Biochemistry University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania
| | - Chunsun Dai
- Department of Pathology University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania
| | - Satdarshan P S Monga
- Department of Pathology University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania,Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania
| |
Collapse
|
27
|
Deguchi A, Miyoshi H, Kojima Y, Okawa K, Aoki M, Taketo MM. LKB1 suppresses p21-activated kinase-1 (PAK1) by phosphorylation of Thr109 in the p21-binding domain. J Biol Chem 2010; 285:18283-90. [PMID: 20400510 DOI: 10.1074/jbc.m109.079137] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The serine/threonine protein kinase LKB1 is a tumor suppressor gene mutated in Peutz-Jeghers syndrome patients. The mutations are found also in several types of sporadic cancer. Although LKB1 is implicated in suppression of cell growth and metastasis, the detailed mechanisms have not yet been elucidated. In this study, we investigated the effect of LKB1 on cell motility, whose acquisition occurs in early metastasis. The knockdown of LKB1 enhanced cell migration and PAK1 activity in human colon cancer HCT116 cells, whereas forced expression of LKB1 in Lkb1-null mouse embryonic fibroblasts suppressed PAK1 activity and PAK1-mediated cell migration simultaneously. Notably, LKB1 directly phosphorylated PAK1 at Thr(109) in the p21-binding domain in vitro. The phosphomimetic T109E mutant showed significantly lower protein kinase activity than wild-type PAK1, suggesting that the phosphorylation at Thr(109) by LKB1 was responsible for suppression of PAK1. Consistently, the nonphosphorylatable T109A mutant was resistant to suppression by LKB1. Furthermore, we found that PAK1 was activated in the hepatocellular carcinomas and the precancerous liver lesions of Lkb1(+/-) mice. Taken together, these results suggest that PAK1 is a direct downstream target of LKB1 and plays an essential role in LKB1-induced suppression of cell migration.
Collapse
Affiliation(s)
- Atsuko Deguchi
- Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan
| | | | | | | | | | | |
Collapse
|